The current challenges faced by people with hemophilia B
European Journal of Haematology · 2024-03 · 112 (3) · 339-349
DOI: 10.1111/ejh.14135 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift European Journal of Haematology, online erschienen am 11.12.2023. Verfasst von Wolfgang Miesbach und 7 weiteren Autor:innen. Beteiligte Einrichtung: University Hospital Frankfurt, Frankfurt, Germany. Hauptthemen laut MEDLINE: Hemophilia B, Hemophilia A. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 79 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: CSL Behring funded medical writing services provided by Nucleus Holdings Ltd.
Abstract (Originalsprache)
Hemophilia B (HB) is a rare, hereditary disease caused by a defect in the gene encoding factor IX (FIX) and leads to varying degrees of coagulation deficiency. The prevailing treatment for people with HB (PWHB) is FIX replacement product. The advent of recombinant coagulation products ushered in a new era of safety, efficacy, and improved availability compared with plasma‐derived products. For people with severe HB, lifelong prophylaxis with a FIX replacement product is standard of care. Development of extended half‐life FIX replacement products has allowed for advancements in the care of these PWHB. Nonetheless, lifelong need for periodic dosing and complex surveillance protocols pose substantive challenges in terms of access, adherence, and healthcare resource utilization. Further, some PWHB on prophylactic regimens continue to experience breakthrough bleeds and joint damage, and subpopulations of PWHB, including women, those with mild‐to‐moderate HB, and those with inhibitors to FIX, experience additional unique difficulties. This review summarizes the current challenges faced by PWHB, including the unique subpopulations; identifying the need for improved awareness, personalized care strategies, and new therapeutic options for severe HB, which may provide future solutions for some of the remaining unmet needs of PWHB.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- University Hospital Frankfurt, Frankfurt, Germany.
- University of California, San Diego, California, USA.
- The Haemophilia Society, London, UK.
- CSL Behring, King of Prussia, Pennsylvania, USA.
- CSL Behring, Mechelen, Belgium.
- Michigan State University Center for Bleeding and Clotting Disorders, Lansing, Michigan, USA.
ORCID-Profile: Wolfgang Miesbach, Annette von Drygalski, Clive Smith, Krupa Sivamurthy, Karen Pinachyan, Debbie Bensen-Kennedy, Douglass Drelich, Roshni Kulkarni
Förderung
- CSL Behring funded medical writing services provided by Nucleus Holdings Ltd
Zitieren
APA
Miesbach, W., von Drygalski, A., Smith, C., Sivamurthy, K., Pinachyan, K., Bensen-Kennedy, D., Drelich, D., & Kulkarni, R. (2024). The current challenges faced by people with hemophilia B. European Journal of Haematology, 112(3), 339-349. https://doi.org/10.1111/ejh.14135
Vancouver
Miesbach W, von Drygalski A, Smith C, Sivamurthy K, Pinachyan K, Bensen-Kennedy D, et al. The current challenges faced by people with hemophilia B. European Journal of Haematology. 2024;112(3):339-349. doi:10.1111/ejh.14135
BibTeX
@article{Miesbach2024,
author = {Miesbach, Wolfgang and von Drygalski, Annette and Smith, Clive and Sivamurthy, Krupa and Pinachyan, Karen and Bensen-Kennedy, Debbie and Drelich, Douglass and Kulkarni, Roshni},
title = {The current challenges faced by people with hemophilia B},
journal = {European Journal of Haematology},
year = {2024},
volume = {112},
number = {3},
pages = {339--349},
doi = {10.1111/ejh.14135}
}
EUVIMED